Riskofrisingpsa.com Website Review

if castration-resistant prostate cancer (crpc) goes undetected in patients receiving adt…. routine psa monitoring may help you identify castration resistance in your patients before metastases emerge. included urologists and oncologists. it was convened to review the currently available imaging guidelines for metastatic disease in prostate cancer and found no consensus on eligibility criteria, type of imaging modality, and the frequency of scanning for detecting metastatic disease. the aim of their review was to present the recommendations from the group to identify optimal strategies for early identification of metastases in patients with prostate cancer.. the american society of clinical oncology (asco) issued a provisional clinical opinion that recommends2: for patients with crpc, no radiographic evidence of metastases, and a slow psa doubling time or velocity, a psa evaluation every 4 to 6 months is reasonable. if psa levels rise, checking serum testosterone levels should be considered. for patients with crpc and a rapid psa doubling time, velocity, or radiographic evidence of metastases, a psa evaluation every 3 months monitoring psa when patients visit to receive their adt may help you identify crpc before the development of metastases. learn about non-metastatic crpc by taking the quiz below featuring 2 hypothetical patients. how much more likely is john to develop a bone metastasis than a patient with non-metastatic crpc who has a psa doubling time ≥10 based on a study that examined psa doubling time and the risk of progression, what is the expected median time to metastasis for john?4 based on his diagnosis of non-metastatic crpc, and his rapid psa doubling time, how frequently should john have his psa measured?1,2 when was kevin’s therapy (androgen-deprivation therapy) first used in the treatment of prostate cancer?6 like many men, kevin initially responded to adt. but after 4 years, he developed crpc. according to one study, what was the median time to